News

Can physical activity actually improve cancer outcomes? Prof. Dr. Nele Adriaenssens (VUB/UZ Brussel) shares why exercise is a "gamechanger" for cancer patients, from reducing chemotherapy side effects to lowering recurrence risks. Learn why personalised rehabilitation is essential before, during, and after treatment in this interview.

New Belgian research, funded by Anticancer Fund and Kom op tegen Kanker, demonstrated that patients with uterine cancer have a significantly better survival rate when treated in hospitals with sufficient experience and expertise. These findings come from the EFFECT study, led by Prof. Dr. Frédéric Amant (University Hospital Leuven), and emphasize the importance of concentrating complex cancer care in specialized centers.

A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast cancer, a trial coordinated by the University of Cambridge has found.

Patients with Acute Myeloid Leukemia (AML) have very few treatment options when the initial chemotherapy has failed. This is particularly true for patients over 60, or with co-morbidities, who are not eligible for stem cell transplantation. On average, they will survive only a few months.

The results of the AML-ViVA trial show that low dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients who do not respond to initial chemotherapy.

A Cambridge-led trial testing a potential new treatment combination for post-menopausal women with hormone driven breast cancer reports positive findings at the international San Antonio Breast Cancer Symposium.

The results show that either a high or low dose of megestrol when given with the standard hormone therapy, letrozole, could be more effective in stopping tumour growth than letrozole alone.

The Anticancer Fund aims to intensify its commitment to helping patients confronted with pancreatic cancer and finding solutions for treatment. As November marks Pancreatic Cancer Awareness Month, we underscore the urgent need for dedicated research during a meeting of the European REMEDi4ALL consortium.